Cinacalcet for the Treatment of Humoral Hypercalcemia of Malignancy: An Introductory Case Report with a Pathophysiologic and Therapeutic Review
Hypercalcemia is an ominous development in the course of malignancy associated with a mean survival of only several months. A majority of cases of hypercalcemia are related to humoral hypercalcemia of malignancy (HHM), where hypercalcemia is caused by increased levels of circulating parathyroid horm...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2020-03-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/506100 |
| _version_ | 1818302180773330944 |
|---|---|
| author | Michael Sheehan Sabo Tanimu Yusuf Tanimu Jessica Engel Adedayo Onitilo |
| author_facet | Michael Sheehan Sabo Tanimu Yusuf Tanimu Jessica Engel Adedayo Onitilo |
| author_sort | Michael Sheehan |
| collection | DOAJ |
| description | Hypercalcemia is an ominous development in the course of malignancy associated with a mean survival of only several months. A majority of cases of hypercalcemia are related to humoral hypercalcemia of malignancy (HHM), where hypercalcemia is caused by increased levels of circulating parathyroid hormone-related protein (PTHrP). Mainstay treatments in the management of HHM are intravenous fluids, intravenous bisphosphonates, and subcutaneous denosumab, although hypercalcemia oftentimes recurs despite these efforts. We present a case of advanced non-small cell lung cancer with PTHrP-mediated hypercalcemia that proved resistant to standard therapy. A trial of oral cinacalcet was initiated and improved calcium levels for 2 months despite a progressive rise in PTHrP and prior to subsequent disease progression. Based on the current body of literature, we propose that this calcium-lowering effect of cinacalcet occurs due to a potential effect on renal calcium excretion. |
| first_indexed | 2024-12-13T05:34:49Z |
| format | Article |
| id | doaj.art-b19427d18ed74210801fd6fd63a70668 |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-13T05:34:49Z |
| publishDate | 2020-03-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-b19427d18ed74210801fd6fd63a706682022-12-21T23:57:58ZengKarger PublishersCase Reports in Oncology1662-65752020-03-0113132132910.1159/000506100506100Cinacalcet for the Treatment of Humoral Hypercalcemia of Malignancy: An Introductory Case Report with a Pathophysiologic and Therapeutic ReviewMichael SheehanSabo TanimuYusuf TanimuJessica EngelAdedayo OnitiloHypercalcemia is an ominous development in the course of malignancy associated with a mean survival of only several months. A majority of cases of hypercalcemia are related to humoral hypercalcemia of malignancy (HHM), where hypercalcemia is caused by increased levels of circulating parathyroid hormone-related protein (PTHrP). Mainstay treatments in the management of HHM are intravenous fluids, intravenous bisphosphonates, and subcutaneous denosumab, although hypercalcemia oftentimes recurs despite these efforts. We present a case of advanced non-small cell lung cancer with PTHrP-mediated hypercalcemia that proved resistant to standard therapy. A trial of oral cinacalcet was initiated and improved calcium levels for 2 months despite a progressive rise in PTHrP and prior to subsequent disease progression. Based on the current body of literature, we propose that this calcium-lowering effect of cinacalcet occurs due to a potential effect on renal calcium excretion.https://www.karger.com/Article/FullText/506100cinacalcethumoral hypercalcemia of malignancypathophysiology |
| spellingShingle | Michael Sheehan Sabo Tanimu Yusuf Tanimu Jessica Engel Adedayo Onitilo Cinacalcet for the Treatment of Humoral Hypercalcemia of Malignancy: An Introductory Case Report with a Pathophysiologic and Therapeutic Review Case Reports in Oncology cinacalcet humoral hypercalcemia of malignancy pathophysiology |
| title | Cinacalcet for the Treatment of Humoral Hypercalcemia of Malignancy: An Introductory Case Report with a Pathophysiologic and Therapeutic Review |
| title_full | Cinacalcet for the Treatment of Humoral Hypercalcemia of Malignancy: An Introductory Case Report with a Pathophysiologic and Therapeutic Review |
| title_fullStr | Cinacalcet for the Treatment of Humoral Hypercalcemia of Malignancy: An Introductory Case Report with a Pathophysiologic and Therapeutic Review |
| title_full_unstemmed | Cinacalcet for the Treatment of Humoral Hypercalcemia of Malignancy: An Introductory Case Report with a Pathophysiologic and Therapeutic Review |
| title_short | Cinacalcet for the Treatment of Humoral Hypercalcemia of Malignancy: An Introductory Case Report with a Pathophysiologic and Therapeutic Review |
| title_sort | cinacalcet for the treatment of humoral hypercalcemia of malignancy an introductory case report with a pathophysiologic and therapeutic review |
| topic | cinacalcet humoral hypercalcemia of malignancy pathophysiology |
| url | https://www.karger.com/Article/FullText/506100 |
| work_keys_str_mv | AT michaelsheehan cinacalcetforthetreatmentofhumoralhypercalcemiaofmalignancyanintroductorycasereportwithapathophysiologicandtherapeuticreview AT sabotanimu cinacalcetforthetreatmentofhumoralhypercalcemiaofmalignancyanintroductorycasereportwithapathophysiologicandtherapeuticreview AT yusuftanimu cinacalcetforthetreatmentofhumoralhypercalcemiaofmalignancyanintroductorycasereportwithapathophysiologicandtherapeuticreview AT jessicaengel cinacalcetforthetreatmentofhumoralhypercalcemiaofmalignancyanintroductorycasereportwithapathophysiologicandtherapeuticreview AT adedayoonitilo cinacalcetforthetreatmentofhumoralhypercalcemiaofmalignancyanintroductorycasereportwithapathophysiologicandtherapeuticreview |